Dr. Streiff's major clinical interest involves the prevention and treatment of venous thromboembolism. He has written several comprehensive reviews on vena caval filters and the management of venous thromboembolism in cancer patients. He chairs the Venous Thromboembolism Guideline Committee for the National Comprehensive Cancer Center Network and has served on international consensus panels to develop standardized guidelines for the use of vena caval filters in the management of venous thromboembolism. As a member of a Johns Hopkins Evidence-Based Practice Center panel, he participated in the development of evidence reports on the management of venous thromboembolism. His research on patients with malignant gliomas identified ABO blood group as a novel risk factor for VTE in this population. A multicenter clinical trial is now nearing completion to confirm these results and identify plasma markers of increased risk for venous thromboembolism in glioma patients. As Medical Director of the Anticoagulation Management Service and Outpatient Clinics, he and his colleagues from the Department of Pharmacy have been actively involved in developing policies and procedures for standardizing anticoagulation management and guidelines for VTE prevention at the Johns Hopkins Medical Institutions. As the consulting Hematologist for the Johns Hopkins Comprehensive Hemophilia Treatment Center, he is actively involved in the diagnosis and treatment of patients with hemophilia, von Willebrand disease and other hemostatic disorders.